AbbVie Gains FDA Approval for SKYRIZI in Pediatric Psoriatic Disease with New 55 mg Pre-Filled Syringe

A new weight-based dosing format is now in scope for fill-finish and device qualification teams: AbbVie has secured FDA approval for risankizumab-rzaa (SKYRIZI) in pediatric patients aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, accompanied by a newly approved 55 mg pre-filled syringe (PFS) designed for patients weighing less than 40 kg. The existing 150 mg PFS and autoinjector pen remain approved for patients at or above that threshold.

The 55 mg PFS represents a distinct device configuration from the commercial 150 mg presentation, which carries direct consequences for manufacturers managing multi-strength biologic portfolios. Fill-finish lines handling the new format will require separate process validation packages, and device qualification under 21 CFR Part 211 must account for the pediatric-specific delivery parameters, including extractables and leachables profiling appropriate to the patient population. Container closure integrity testing and primary packaging specifications will need to be assessed independently of the adult presentation.

The pediatric psoriasis indication is supported by data from the Phase 3 OptIMMize clinical trial program (NCT04435600; NCT04862286), encompassing pharmacokinetic cohorts, a randomized efficacy assessor-blinded active-controlled cohort in adolescents aged 12 to under 18, and a single-arm open-label cohort in children aged 6 to under 12. The psoriatic arthritis indication in pediatric patients draws on the same psoriasis trial data supplemented by population pharmacokinetic modeling derived from well-controlled adult psoriatic arthritis studies. The observed pediatric safety profile was consistent with the established adult profile.

For QA directors, the regulatory pathway here is instructive: population PK modeling and simulation, rather than a dedicated pediatric PsA efficacy trial, formed part of the submission basis. This approach, increasingly accepted under ICH E11(R1) guidance on pediatric studies, signals that regulators are willing to extrapolate adult efficacy data when the disease course and drug mechanism are sufficiently understood. Labeling teams and regulatory affairs leads should note how this extrapolation strategy is documented in the approved prescribing information as a reference point for analogous pediatric submissions.

With approximately 20,000 children under ten diagnosed with psoriasis annually in the U.S. and an estimated 14,000 pediatric patients affected by psoriatic arthritis, commercial demand for the 55 mg presentation is not marginal. Supply chain planners will need to account for a separate SKU with its own cold-chain and serialization requirements under DSCSA obligations.

The measurable checkpoint ahead is the commercial launch trajectory for the 55 mg PFS and whether AbbVie's fill-finish network can sustain dual-strength supply continuity without compromising sterility assurance levels across both presentations.

Source: AbbVie News Center via PR Newswire, 26 June 2026.